brusatol has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afolabi, LO; Chen, L; Feng, X; Li, J; Zhang, J; Zhu, Y | 1 |
| Balasubramaniam, J; Chandrasekaran, J; Ravi, A; Sellamuthu, A | 1 |
2 other study(ies) available for brusatol and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway.
Topics: Cell Line, Tumor; Humans; NF-E2-Related Factor 2; Signal Transduction; Triple Negative Breast Neoplasms | 2023 |
An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Quassins; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2021 |